Celldex Therapeutics Stock Today
| CLDX Stock | USD 39.63 1.03 2.67% |
Performance1 of 100
| Odds Of DistressLess than 42
|
Celldex Therapeutics is trading at 39.63 as of the 17th of April 2024; that is 2.67 percent increase since the beginning of the trading day. The stock's open price was 38.6. Celldex Therapeutics has about a 42 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Celldex Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 18th of March 2024 and ending today, the 17th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 10th of March 2008 | Category Healthcare | Classification Health Care |
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey. The company has 65.7 M outstanding shares of which 6.56 M shares are currently shorted by private and institutional investors with about 5.5 trading days to cover. More on Celldex Therapeutics
Moving against Celldex Stock
| 0.47 | SBFMW | Sunshine Biopharma | PairCorr |
| 0.43 | VBIV | VBI Vaccines Financial Report 20th of May 2024 | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 2nd of May 2024
Celldex Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Celldex Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Celldex Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President CEO, Director | Anthony Marucci | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Cancer Fighters (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Celldex Therapeutics report their recommendations after researching Celldex Therapeutics' financial statements, talking to executives and customers, or listening in on Celldex Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Celldex Therapeutics. The Celldex consensus assessment is calculated by taking the average forecast from all of the analysts covering Celldex Therapeutics. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Celldex Therapeutics' liquidity, profitability, solvency, and operating efficiency, Celldex Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. Financial strength of Celldex Therapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Celldex Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Celldex Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Celldex Therapeutics' financial leverage. It provides some insight into what part of Celldex Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Celldex Therapeutics (CLDX) is traded on NASDAQ Exchange in USA. It is located in Perryville III Building, Hampton, NJ, United States, 08827 and employs 160 people. Celldex Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.57 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Celldex Therapeutics's market, we take the total number of its shares issued and multiply it by Celldex Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Celldex Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 65.7 M outstanding shares of which 6.56 M shares are currently shorted by private and institutional investors with about 5.5 trading days to cover.
Celldex Therapeutics currently holds about 356.82 M in cash with (107.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.63.
Check Celldex Therapeutics Probability Of Bankruptcy
Ownership AllocationCelldex Therapeutics holds a total of 65.7 Million outstanding shares. The majority of Celldex Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Celldex Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Celldex Therapeutics. Please pay attention to any change in the institutional holdings of Celldex Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Celldex Ownership Details
Celldex Stock Price Odds Analysis
Based on a normal probability distribution, the odds of Celldex Therapeutics jumping above the current price in 90 days from now is about 62.04%. The Celldex Therapeutics probability density function shows the probability of Celldex Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.1283 suggesting Celldex Therapeutics market returns are sensitive to returns on the market. As the market goes up or down, Celldex Therapeutics is expected to follow. Additionally, celldex Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Celldex Therapeutics to move above the current price in 90 days from now is about 62.04 (This Celldex Therapeutics probability density function shows the probability of Celldex Stock to fall within a particular range of prices over 90 days) .
Celldex Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Celldex Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Celldex Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Celldex Therapeutics' value.| Instituion | Recorded On | Shares | |
| Redmile Group, Llc | 2023-09-30 | 1.6 M | |
| Point72 Asset Management, L.p. | 2023-09-30 | 1.3 M | |
| Marshall Wace Asset Management Ltd | 2023-12-31 | 1.3 M | |
| Geode Capital Management, Llc | 2023-12-31 | 1.1 M | |
| Rock Springs Capital Management Lp | 2023-12-31 | 969.6 K | |
| Goldman Sachs Group Inc | 2023-12-31 | 875.5 K | |
| Sofinnova Ventures | 2023-12-31 | 844 K | |
| Octagon Capital Advisors Lp | 2023-09-30 | 759.9 K | |
| Eversept Partners, Llc | 2023-12-31 | 754.1 K | |
| Fmr Inc | 2023-12-31 | 7.1 M | |
| Wellington Management Company Llp | 2023-12-31 | 6.5 M |
Celldex Therapeutics Historical Income Statement
Celldex Therapeutics Income Statement is one of the three primary financial statements used for reporting Celldex's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Celldex Therapeutics revenue and expense. Celldex Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Celldex Therapeutics' Total Revenue is fairly stable compared to the past year. Other Operating Expenses is likely to rise to about 156.4 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 2.6 M in 2024. View More FundamentalsCelldex Stock Against Markets
Picking the right benchmark for Celldex Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Celldex Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Celldex Therapeutics is critical whether you are bullish or bearish towards Celldex Therapeutics at a given time. Please also check how Celldex Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Celldex Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Fundamental Analysis Now
Fundamental AnalysisView fundamental data based on most recent published financial statements |
| All Next | Launch Module |
Celldex Therapeutics Corporate Directors
Celldex Therapeutics corporate directors refer to members of a Celldex Therapeutics board of directors. The board of directors generally takes responsibility for the Celldex Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Celldex Therapeutics' board members must vote for the resolution. The Celldex Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Keith Brownlie | Director | Profile | |
| Gerald McMahon | Director | Profile | |
| James Marino | Director | Profile | |
| George Elston | Independent Director | Profile |
How to buy Celldex Stock?
Before investing in Celldex Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Celldex Therapeutics. To buy Celldex Therapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Celldex Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Celldex Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Celldex Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Celldex Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Celldex Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Celldex Stock please use our How to Invest in Celldex Therapeutics guide.
Already Invested in Celldex Therapeutics?
The danger of trading Celldex Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Celldex Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Celldex Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Celldex Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Celldex Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Celldex Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Celldex Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Celldex Therapeutics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Celldex Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy Celldex Stock please use our How to Invest in Celldex Therapeutics guide.Note that the Celldex Therapeutics information on this page should be used as a complementary analysis to other Celldex Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Complementary Tools for Celldex Stock analysis
When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |
Is Celldex Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Celldex Therapeutics. If investors know Celldex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Celldex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.92) | Revenue Per Share 0.142 | Quarterly Revenue Growth 1.561 | Return On Assets (0.22) | Return On Equity (0.37) |
The market value of Celldex Therapeutics is measured differently than its book value, which is the value of Celldex that is recorded on the company's balance sheet. Investors also form their own opinion of Celldex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Celldex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Celldex Therapeutics' market value can be influenced by many factors that don't directly affect Celldex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Celldex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Celldex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Celldex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.